Johnson & Johnson is charting a new path for clinical trial submissions; one built on transparency, efficiency, and collaboration through open-source tooling and R.

In this recorded session, J&J’s data science team shares how they’re evolving their late-stage clinical trial processes using open-source tools. From adoption hurdles to long-term strategy, they offer a behind-the-scenes look at what it takes to bring open-source into a highly regulated, enterprise environment, and why it’s worth it.

Key topics you'll learn about:
• The practical realities of implementing R at scale within a large pharma organization
• How open-source packages are streamlining data workflows and regulatory preparation
• J&J’s roadmap for broader adoption and community engagement through 2025
• Lessons learned from engaging with health authorities using R-generated outputs
• The growing role of the pharmaverse in shaping modern clinical research infrastructure